Updated CEO Interview Coming Tomorrow Print E-mail
By M.E.Garza   
Tuesday, 27 April 2010 12:39

We will feature an updated, fully press-released interview with the CEO of Positron Corp. (POSC.OB) tomorrow morning.

Yesterday, the company confirmed that they will be holding a press conference next week and today they issued a breif description of the press conference agenda.

As we told you last week, it is expected that some very positive developments will be highlighted and that the company will emerge as the clear leader in molecular imaging devices/software for cardiology in the United States and internationally.

Some key details about a big partnership which will be revealed at the press conference can not be discussed until early May, but we fully expect that the stock will trade higher as the press conference date approaches in anticipation of that news and our interview with the CEO will attempt to put some of those topics and their effects on the company's market-cap in perspective.

Text of today's company's press release is below:

Positron Corporation (OTCBB:POSC), a molecular imaging solutions company focused on Nuclear Cardiology, today announced that its CEO Patrick G. Rooney and senior executives will present at the NASDAQ MarketSite in Times Square, New York City, NY.

Topics to include: The Company will introduce business initiatives and certain strategic alliances with industry leading companies and will address how certain opportunities will impact the industry and the Company.

Senior Executives will discuss the Company's leadership role in the Nuclear Medicine industry and the immediate demand driving Cardiac PET (positron emission tomography) as a result of many positive industry factors pushing Cardiac PET as the preferred nuclear cardiology imaging modality. In addition, Positron Executives will discuss the Company's revolutionary radiopharmaceutical distribution devices as to how they enable disintermediation by manufacturers, wholesalers and consumers alike.

Additional information will be given about the Company's patient injection device as it applies to patient care and worker safety with oncology and cardiology therapeutic and diagnostic radiopharmaceuticals.

When: May 5, 2010, 1:00 pm EDT

Where: NASDAQ MarketSite, 4 Times Square, New York, NY


Disclosure: I am still long POSC and have not sold or transacted any shares since my initial buy.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus